Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...

Panelists discuss how the CEPHEUS trial demonstrated that quadruplet therapy (daratumumab, bortezomib, lenalidomide, and dexamethasone) significantly improved minimal residual disease negativity rates ...

An expert discusses how adding an anti-CD38 antibody to a triplet backbone improved minimal residual disease (MRD) negativity and progression-free survival (PFS) in frail, transplant-ineligible ...

MiROM identifies proteins by using mid-infrared light to detect molecular vibrations – essentially the natural "dance" of molecules within protein structures. Unlike optical spectroscopy, which ...

Multiple myeloma involves a comprehensive approach that combines blood tests, imaging, and bone marrow studies. Learn about ...

Medically reviewed by Archana Sharma, DO There are several treatment options for multiple myeloma. Since this disease varies ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...